PL3310805T3 - Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie - Google Patents
Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynieInfo
- Publication number
- PL3310805T3 PL3310805T3 PL16736802T PL16736802T PL3310805T3 PL 3310805 T3 PL3310805 T3 PL 3310805T3 PL 16736802 T PL16736802 T PL 16736802T PL 16736802 T PL16736802 T PL 16736802T PL 3310805 T3 PL3310805 T3 PL 3310805T3
- Authority
- PL
- Poland
- Prior art keywords
- medicine
- application
- fusion proteins
- fusion
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 | ||
| EP16736802.6A EP3310805B1 (en) | 2015-06-19 | 2016-06-20 | Pd-1-cd28 fusion proteins and their use in medicine |
| PCT/EP2016/064195 WO2016203048A1 (en) | 2015-06-19 | 2016-06-20 | Pd-1-cd28 fusion proteins and their use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3310805T3 true PL3310805T3 (pl) | 2021-08-23 |
Family
ID=53476720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16736802T PL3310805T3 (pl) | 2015-06-19 | 2016-06-20 | Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (pl) |
| EP (3) | EP3310805B1 (pl) |
| JP (3) | JP7085988B2 (pl) |
| CN (3) | CN115925971A (pl) |
| AU (1) | AU2016277883B2 (pl) |
| CA (1) | CA2989949A1 (pl) |
| DK (2) | DK3909972T5 (pl) |
| ES (2) | ES2870174T3 (pl) |
| FI (1) | FI3909972T3 (pl) |
| HU (1) | HUE054201T2 (pl) |
| PL (1) | PL3310805T3 (pl) |
| PT (1) | PT3310805T (pl) |
| WO (1) | WO2016203048A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141357A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| HUE051661T2 (hu) | 2015-05-18 | 2021-03-29 | Tcr2 Therapeutics Inc | Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával |
| HUE054201T2 (hu) * | 2015-06-19 | 2021-08-30 | Endres Stefan Prof Dr | PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk |
| HK1255637A1 (zh) * | 2015-06-29 | 2019-08-23 | The Johns Hopkins University | 免疫检查点嵌合受体疗法 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109195985B (zh) | 2016-03-23 | 2022-07-26 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | Pd-1和4-1bb的融合蛋白 |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| JP7175769B2 (ja) * | 2016-06-30 | 2022-11-21 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 改善された養子ｔ細胞療法 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| US20210187022A1 (en) * | 2016-12-21 | 2021-06-24 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| EP4043485A1 (en) * | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| CN119409836A (zh) | 2017-03-17 | 2025-02-11 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| AU2019231205A1 (en) | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| CN120944827A (zh) * | 2019-03-27 | 2025-11-14 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| CN120988097A (zh) * | 2021-04-11 | 2025-11-21 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| US20240252613A1 (en) * | 2021-05-20 | 2024-08-01 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| CN121057753A (zh) * | 2022-11-14 | 2025-12-02 | 阿奇洛伊斯生物制药公司 | 免疫检查点多价颗粒组合物和使用方法 |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
| US20110280894A1 (en) | 2008-07-31 | 2011-11-17 | Angela Krackhardt | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PT3459560T (pt) | 2011-04-08 | 2021-05-24 | Us Health | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro |
| EA201490364A1 (ru) * | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| US9359447B2 (en) | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| KR20240136359A (ko) | 2012-04-11 | 2024-09-13 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN105940102B (zh) | 2013-08-26 | 2020-02-18 | 海瑞克·亚柏坎 | 抗cd30嵌合抗原受体及其用途 |
| US9650428B2 (en) | 2014-12-02 | 2017-05-16 | Roger Williams Hospital | Methods and compositions for treating cancer |
| WO2016141357A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| HUE054201T2 (hu) | 2015-06-19 | 2021-08-30 | Endres Stefan Prof Dr | PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk |
| CN114133448A (zh) | 2015-06-23 | 2022-03-04 | 纪念斯隆-凯特琳癌症中心 | 新型pd-1免疫调节剂 |
| HK1255637A1 (zh) | 2015-06-29 | 2019-08-23 | The Johns Hopkins University | 免疫检查点嵌合受体疗法 |
| HK1258041A1 (zh) | 2015-09-04 | 2019-11-01 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物和使用方法 |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CA3007980A1 (en) | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| CN109195985B (zh) | 2016-03-23 | 2022-07-26 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | Pd-1和4-1bb的融合蛋白 |
| EP3525805A4 (en) | 2016-12-22 | 2020-07-29 | Windmil Therapeutics, Inc. | COMPOSITIONS AND METHODS OF MODULATION OF THE IMMUNE SYSTEM |
| AU2018327225A1 (en) | 2017-09-06 | 2020-02-27 | Fred Hutchinson Cancer Center | Strep-tag specific chimeric receptors and uses thereof |
| CN110951718B (zh) * | 2019-12-02 | 2022-09-30 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
-
2021
- 2021-10-29 US US17/515,250 patent/US12570718B2/en active Active
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4349854A3 (en) | 2024-07-10 |
| HUE054201T2 (hu) | 2021-08-30 |
| DK3310805T3 (da) | 2021-05-03 |
| JP2024073636A (ja) | 2024-05-29 |
| US11192935B2 (en) | 2021-12-07 |
| EP4349854A2 (en) | 2024-04-10 |
| AU2016277883A8 (en) | 2018-01-25 |
| EP3310805A1 (en) | 2018-04-25 |
| CA2989949A1 (en) | 2016-12-22 |
| AU2016277883B2 (en) | 2020-09-17 |
| US12570718B2 (en) | 2026-03-10 |
| US20190010207A1 (en) | 2019-01-10 |
| EP3909972A1 (en) | 2021-11-17 |
| CN108026151B (zh) | 2022-07-15 |
| ES2976647T3 (es) | 2024-08-06 |
| CN115925971A (zh) | 2023-04-07 |
| ES2870174T3 (es) | 2021-10-26 |
| CN115927474A (zh) | 2023-04-07 |
| WO2016203048A1 (en) | 2016-12-22 |
| JP2018518990A (ja) | 2018-07-19 |
| JP7085988B2 (ja) | 2022-06-17 |
| US20220169699A1 (en) | 2022-06-02 |
| EP3909972B1 (en) | 2024-02-14 |
| PT3310805T (pt) | 2021-05-19 |
| JP7460675B2 (ja) | 2024-04-02 |
| DK3909972T5 (da) | 2024-08-05 |
| JP2022084787A (ja) | 2022-06-07 |
| EP3310805B1 (en) | 2021-02-17 |
| CN108026151A (zh) | 2018-05-11 |
| DK3909972T3 (da) | 2024-04-29 |
| AU2016277883A1 (en) | 2018-01-18 |
| FI3909972T3 (fi) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3310805T3 (pl) | Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie | |
| IL289276A (en) | Treprostinil derivatives and compositions and uses thereof | |
| IL254165A0 (en) | Immunomodulatory fusion proteins and uses thereof | |
| IL262652A (en) | Gdf15 fusion proteins and uses thereof | |
| SI3383916T1 (sl) | Protitelesa proti-CD73 in njihove uporabe | |
| IL262092A (en) | Humanized anti-pacap antibodies and uses thereof | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| IL255697A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| IL255912A (en) | Compositions and methods for degradation of misfolded proteins | |
| PL3653221T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| DK3368555T3 (da) | Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse | |
| PL3280441T3 (pl) | Przeciwciała przeciwko sortilinie i sposoby ich stosowania | |
| SI3443009T1 (sl) | Protitelesa proti-TIM-3 in sestavki | |
| PL3303396T3 (pl) | Przeciwciała przeciwko ox40 i ich zastosowanie | |
| HRP20190028T1 (hr) | Interleukin-2 fuzijski proteini i njihove primjene | |
| HRP20260195T1 (hr) | Proteini koji vežu anti-tl1a antigen i njihova upotreba | |
| SI3565828T1 (sl) | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| DK3292141T3 (da) | Fusionsproteiner | |
| DK3280727T3 (da) | Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf | |
| DK3368554T3 (da) | Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme | |
| EP2968551A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| PL3498292T3 (pl) | Konstrukty białka uspa2 i ich zastosowania | |
| DK3322734T3 (da) | Multivalente og multispecifikke DR5-bindende fusionsproteiner |